Current projects include: (1) Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Data Coordinating Center to conduct multicenter clinical trials, epidemiological, and therapeutic research in nonalcoholic fatty liver disease (NAFLD) and NASH patients; (2) Gastroparesis Clinical Research Consortium Data Coordinating Center to conduct multicenter clinical trials and observational studies to investigate the etiology, natural history, and management of gastroparesis; (3) Preservation of Vascular Access Study (PVAS) Coordinating Center to conduct a retrospective, observational study designed to evaluate the use of SyvekPatch®, manufactured by the MPT, in extending the life of arteriovenous (AV) fistulas and AV grafts in hemodialysis patients.

epidemiology, multicenter clinical trials, drug approval, NASH, NAFLD, gastroparesis

Doctoral Fellowship, 1994-99, The Turkish Higher Education Council

Postdoctoral Training Grant, 1999-00, The Johns Hopkins Center for Clinical Trials

Brunt EM, Kleiner DE, Wilson LA, Ünalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD - clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology Epub 2008 November 5.

Writing Committee member (Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Ünalp A, Tonascia J) for the NASH CRN. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 30: 88-96, 2009.

Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Ünalp A; for the NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48: 829-834, 2008.

Neuschwander-Tetri BA, Ünalp A, Creer MH; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med 168: 663-666, 2008.

Ünalp A, Tonascia S, Meinert CL. Presentation in relation to publication of results from clinical trials. Contemp Clin Trials 28: 358-369, 2007.

Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56: 2382-2391, 2007.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ for the Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321, 2005

Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Ünalp A, Gordon G, Forastiere AA; CBET Research Group. Chemoprevention for Barrett's esophagus trial: Design and outcome measures. Dis Esophagus 16:177-186, 2003

Unalp A, Shafer C, Tonascia S, Meinert CL. FDA censoring of manufacturers' postmarketing commitments in HIV/AIDS drug approval letters. Am J Ther 7: 257-263, 2000

Meinert CL, Gilpin AK, Unalp A, Dawson C. Gender representation in trials. Control Clin Trials 21: 462-475, 2000

Gencbay M, Degertekin M, Ermeydan C, Unalp A, Turan F. Exercise electrocardiography test in patients with aortic stenosis. Differential features from that of coronary artery disease. Int J Cardiol 69: 281-287, 1999

Gencbay M, Turan F, Degertekin M, Eksi N, Mutlu B, Unalp A. High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves. J Heart Valve Dis 7: 601-609, 1998

Unalp-Arida A. Time lag bias in publishing clinical trials [letter]. JAMA 279: 1952, 1998

Unalp A, Ruacan S, Firat D. Hospital-based cancer registry. Turk J Cancer 24: 127-137, 1994